| Title: | Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes |
| Journal: | Journal of Translational Medicine |
| Published: | 6 Jul 2023 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/37415201/ |
| DOI: | https://doi.org/10.1186/s12967-023-04316-y |
| URL: | https://translational-medicine.biomedcentral.com/counter/pdf/10.1186/s12967-023-04316-y |
| Citations: | 1 (1 in last 2 years) as of 8 Aug 2024 |
Publication 11619
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundThe genetic risk of aggressive prostate cancer (PCa) is hard to be assessed due to the lack of aggressiveness-related single-nucleotide polymorphisms (SNPs). Prostate volume (PV) is a potential well-established risk factor for aggressive PCa, we hypothesize that polygenic risk score (PRS) based on benign prostate hyperplasia (BPH) or PV-related SNPs may also predict the risk of aggressive PCa or PCa death.MethodsWe evaluated a PRS using 21 BPH/PV-associated SNPs, two established PCa risk-related PRS and 10 guideline-recommended hereditary cancer risk genes in the population-based UK Biobank cohort (N = 209,502).ResultsThe BPH/PV PRS was significantly inversely associated with the incidence of lethal PCa as well as the natural progress in PCa patients (hazard ratio, HR = 0.92, 95% confidence interval [CI]: 0.87-0.98, P = 0.02; HR = 0.92, 95% CI 0.86-0.98, P = 0.01). Compared with men at the top 25th PRS, PCa patients with bottom 25th PRS would have a 1.41-fold (HR, 95% CI 1.16-1.69, P = 0.001) increased PCa fatal risk and shorter survival time at 0.37 yr (95% CI 0.14-0.61, P = 0.002). In addition, patients with BRCA2 or PALB2 pathogenic mutations would also have a high risk of PCa death (HR = 3.90, 95% CI 2.34-6.51, P = 1.79 × 10-7; HR = 4.29, 95% CI 1.36-13.50, P = 0.01, respectively). However, no interactive but independent effects were detected between this PRS and pathogenic mutations.ConclusionsOur findings provide a new measurement of PCa patients' natural disease outcomes via genetic risk ways.</p>
5 Authors
- Xiaohao Ruan
- Da Huang
- Jingyi Huang
- James Hok-Leung Tsu
- Rong Na
1 Application
| Application ID | Title |
|---|---|
| 66813 | Comprehensive evaluation of causal relationship among different phenotypes and disease traits by Mendelian Randomization using Genetic Instruments |
Enabling scientific discoveries that improve human health